Effect of a Third COVID-19 Booster Among Health Care Workers

Overview

A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022. In response, the administration of a third dose of COVID-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the Omicron/ Delta variant. The pandemic also resulted in many infections among health care workers (HCWs) and their households. In this study, a retrospective analysis would perform on risk of COVID-19 infection and their outcome in relation to their COVID-19 vaccination history by using the data repository from one of the Hong Kong private hospitals. HCWs were required to submit a standardized online self-declaration form for report of 1) demographic of the HCWs, 2) symptoms related history and 3) COVID-19 exposure history once they were COVID-19 confirmed by rapid antigen test against COVID-19 and/or polymerase chain reaction (PCR) test for COVID-19. Subsequent follow up such as contact tracing, COVID-19 PCR testing results of these HCWs and status of return to work were captured by the infection control team in a systematic manner.

Full Title of Study: “Effect of a Third COVID-19 Booster on COVID-19 Infection Rate and Return to Works During Fifth Wave COVID-19 Among Health Care Workers”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 31, 2022

Interventions

  • Biological: Third COVID-19 booster
    • Third COVID-19 booster

Arms, Groups and Cohorts

  • Health care workers without third COVID-19 booster
    • Health care workers received less than 3 doses of COVID-19 vaccine
  • HCWs with third COVID-19 booster
    • Health care workers received at least 3 doses of COVID-19 vaccine

Clinical Trial Outcome Measures

Primary Measures

  • COVID-19 Infection
    • Time Frame: During 1 February – 31 March 2022
    • Infection of COVID-19
  • Number of days return to work after COVID-19 infection
    • Time Frame: During 1 February – 31 March 2022
    • Number of days return to work after COVID-19 infection

Participating in This Clinical Trial

Inclusion Criteria

  • All full time staff members of the private hospital Exclusion Criteria:

  • History of COVID-19 before 2022

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Hong Kong Sanatorium & Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Jonpaul ST Zee, Specialist in Infectious Disease – Hong Kong Sanatorium & Hospital
  • Overall Official(s)
    • Jonpaul Sze Tsing Zee, MBChB, Principal Investigator, Hong Kong Sanatorium & Hospital
  • Overall Contact(s)
    • Jonpaul Sze Tsing Zee, MBChB, 28357064, Jonpaul.ST.Zee@hksh.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.